SCHEMBL509838

SCHEMBL509838

CNCCCC1CC=CCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.44
HTR2A P28223 2/20 0.34
HRH1 P35367 2/20 0.34
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.32
KDM4E B2RXH2 4/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CHRM2 P08172 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CHRM1 P11229 1/20 0.32
DRD2 P14416 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
NFKB1 P19838 1/20 0.32
CHRM3 P20309 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2C P28335 1/20 0.32
ADRA1A P35348 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864355 0.88 SIGMAR1 (0.34) SIGMAR1HTR2AHRH1MAPTMAPK1
SCHEMBL5864342 0.86 SIGMAR1 (0.47) SIGMAR1HTR2AHRH1MAPTKDM4E
SCHEMBL2136195 0.81 MAPK1 (0.38) SIGMAR1MAPK1KDM4ECYP2D6HSD17B10
SCHEMBL2141114 0.81 MAPK1 (0.38) MAPK1KDM4ECYP2D6HSD17B10ALDH1A1
SCHEMBL11075927 0.79 MAPK1 (0.37) SIGMAR1MAPK1KDM4EHSD17B10ALDH1A1
SCHEMBL2138060 0.79 MAPK1 (0.37) SIGMAR1MAPK1KDM4EHSD17B10ALDH1A1
SCHEMBL1524848 0.78 CYP1A2 (0.46) MAPTMAPK1KDM4ELMNACYP2D6
SCHEMBL17580303 0.76 ALDH1A1 (0.39) MAPK1KDM4ELMNACYP2D6HSD17B10
SCHEMBL1524898 0.76 CYP1A2 (0.40) MAPK1KDM4ELMNACYP2D6HSD17B10
SCHEMBL2621463 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1066337-B1 OXYGEN SCAVENGERS WITH REDUCED OXIDATION PRODUCTS FOR USE IN PLASTIC FILMS AND BEVERAGE AND FOOD CONTAINERS CHEVRON PHILLIPS CHEMICAL CO (US) 2004-11-03 EP claimed
EP-1066337-A2 OXYGEN SCAVENGERS WITH REDUCED OXIDATION PRODUCTS FOR USE IN PLASTIC FILMS AND BEVERAGE AND FOOD CONTAINERS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2001-01-10 EP claimed
WO-1999048963-A2 OXYGEN SCAVENGERS WITH REDUCED OXIDATION PRODUCTS FOR USE IN PLASTIC FILMS AND BEVERAGE AND FOOD CONTAINERS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 1999-09-30 WO claimed
US-20220218713-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2022-07-14 US disclosed
US-20210113571-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2021-04-22 US disclosed
US-20200281933-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2020-09-10 US disclosed
US-20200030335-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2020-01-30 US disclosed
US-20190175603-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2019-06-13 US disclosed
US-20180303842-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2018-10-25 US disclosed
US-20170266194-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2017-09-21 US disclosed
EP-2380874-B1 Pleuromutilin derivatives for the treatment of diseases mediated by microbes NABRIVA THERAPEUTICS AG (AT) 2016-12-28 EP disclosed
US-20120029072-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG 2012-02-02 US disclosed
US-8071643-B2 Pleuromutilin derivatives for the treatment of diseases mediated by microbes NABRIVA THERAPEUTICS AG (AT) 2011-12-06 US disclosed
EP-2380874-A2 Pleuromutilin derivatives for the treatment of diseases mediated by microbes Nabriva Therapeutics AG (AT) 2011-10-26 EP disclosed
EP-2137143-B1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG (AT) 2011-09-07 EP disclosed
US-20100035987-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG (AT) 2010-02-11 US disclosed
US-7097890-B1 Polymer with pendent cyclic olefinic functions for oxygen scavenging packaging CHEVRON PHILLIPS CHEMICAL CO. LP (US) 2006-08-29 US disclosed
EP-1066337-B1 OXYGEN SCAVENGERS WITH REDUCED OXIDATION PRODUCTS FOR USE IN PLASTIC FILMS AND BEVERAGE AND FOOD CONTAINERS CHEVRON PHILLIPS CHEMICAL CO (US) 2004-11-03 EP disclosed
EP-1066337-A2 OXYGEN SCAVENGERS WITH REDUCED OXIDATION PRODUCTS FOR USE IN PLASTIC FILMS AND BEVERAGE AND FOOD CONTAINERS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2001-01-10 EP disclosed
WO-1999048963-A2 OXYGEN SCAVENGERS WITH REDUCED OXIDATION PRODUCTS FOR USE IN PLASTIC FILMS AND BEVERAGE AND FOOD CONTAINERS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 1999-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200281933-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, PLEC, FABP6 SIGMAR1 4396/4885HTR2A 3485/4885HRH1 190/4885
US-20220218713-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, PLEC, FABP6 SIGMAR1 4368/4885HTR2A 3551/4885HRH1 196/4885
US-20190175603-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, PLEC, FABP6 SIGMAR1 4396/4885HTR2A 3485/4885HRH1 190/4885
US-20170266194-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HRH4, HRH2, CHRM1 SIGMAR1 750/4885HTR2A 1941/4885HRH1 7/4885
US-20100035987-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, FABP6, ALPI SIGMAR1 4129/4885HTR2A 4026/4885HRH1 416/4885
US-20200030335-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES HRH4, HRH2, CHRM1 SIGMAR1 750/4885HTR2A 1941/4885HRH1 7/4885
US-20210113571-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, PLEC, FABP6 SIGMAR1 4368/4885HTR2A 3551/4885HRH1 196/4885
US-20180303842-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, PLEC, FABP6 SIGMAR1 4396/4885HTR2A 3485/4885HRH1 190/4885
US-20120029072-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, FABP6, PLEC SIGMAR1 4169/4885HTR2A 3374/4885HRH1 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.